Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CP12-0710 | Other Identifier | ImClone Systems | |
| I4T-IE-JVBQ | Other Identifier | Eli Lilly and Company |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A study to determine how long ramucirumab (IMC-1121B) will stop cancer from growing in participants with liver cancer that cannot be treated with surgery.
Inhibition of angiogenesis is considered a promising approach to the treatment of cancer. Members of the vascular endothelial growth factor (VEGF) family and the VEGF receptor-2 (VEGFR-2) are important mediators of angiogenesis and are likely important therapeutic targets in advanced hepatocellular cancer (HCC).
Angiogenesis appears integral to HCC development and pathogenesis. Angiogenesis inhibition has been efficacious in both in vitro and in vivo HCC models and results of clinical studies also suggest potential to inhibit disease growth.
Ramucirumab is a fully human monoclonal antibody (MAb) that specifically binds to the extracellular domain of VEGFR-2 with high affinity. Phase 1 studies currently nearing completion have demonstrated safety and tolerability at clinically relevant doses, with preliminary evidence of clinical efficacy in a variety of human cancers.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ramucirumab (IMC-1121B) | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ramucirumab (IMC-1121B) | Biological | Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. |
| Measure | Description | Time Frame |
|---|---|---|
| Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab | PFS was defined as the time from the first day of therapy to the first evidence of disease progression or death from any cause. As classified according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Participants who were alive and without disease progression and participants who did not progress and were subsequently lost to follow-up were censored at the last objective tumor assessment. | First dose to date of progressive disease or death due to any cause [every 3 cycles up to 18 months (1 cycle=2 weeks)] |
| Measure | Description | Time Frame |
|---|---|---|
| Time to Progression | The time from first day of therapy to the first date of objective evidence of progressive disease (PD) by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD was defined as having at least a 20% increase in sum of longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of new lesion. Time to PD was censored at the date of death or study discontinuation. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) | Eli Lilly and Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ImClone Investigational Site | Los Angeles | California | 90095 | United States | ||
| ImClone Investigational Site |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Ramucirumab (IMC-1121B) | Ramucirumab (IMC-1121B): 8 milligrams per kilogram (mg/kg) administered intravenously over 1 hour, every 2 weeks. Treatment continued until there was evidence of disease progression, intolerable toxicity, or other withdrawal criteria were met. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| First dose to date of PD [every 3 cycles up to 18 months (1 cycle=2 weeks)] |
| Overall Survival | Overall survival (OS) was the duration from first dose to death due to any cause. OS was censored at last contact date for participants who were alive at the end of follow-up period or lost to follow-up. | First dose to death due to any cause up to 37.5 months |
| Percentage of Participants With Complete Response or Partial Response (Objective Response Rate) | Objective response rate (ORR) was defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). As classified according to Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria, CR was the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeters (mm) and normalization of tumor marker level of non-target lesions. PR was having at least a 30% decrease in sum of longest diameter of target lesions. | First dose to date of objective progressive disease (PD) or death up to 18 months |
| Duration of Response | Duration of response was the interval from the date of initial documented response [complete response (CR) or partial response (PR)] to the first documented date of disease progression, initiation of other (or additional) antitumor therapy was first reported, or death due to any cause. As classified according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, CR was the disappearance of all target lesions, PR was having at least a 30% decrease in the sum of the longest diameter of target lesions, and disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Data were censored for participants who did not progress or die. | Time of first response (CR or PR) to disease progression, or death due to any cause [every 3 cycles up to 18 months (1 cycle=2 weeks)] |
| Number of Participants With Serum Anti-Ramucirumab Antibodies | Prior to dosing at baseline, Cycles 4 and 7, and 30 days after end of therapy (1 cycle=2 weeks) |
| Number of Participants With Drug-Related Treatment-Emergent Adverse Events | Data presented are the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3 or higher TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered by the investigator to be related to ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section. | First dose to 37.5 months |
| Chicago |
| Illinois |
| 60611 |
| United States |
| ImClone Investigational Site | Metairie | Louisiana | 70006 | United States |
| ImClone Investigational Site | Boston | Massachusetts | 02114 | United States |
| ImClone Investigational Site | Burlington | Massachusetts | 01805 | United States |
| ImClone Investigational Site | Philadelphia | Pennsylvania | 19104 | United States |
| Received at Least 1 Dose of Study Drug |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Participants who received at least 1 dose of ramucirumab.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Ramucirumab (IMC-1121B) | Ramucirumab (IMC-1121B): 8 milligrams per kilogram (mg/kg) administered intravenously over 1 hour, every 2 weeks. Treatment continued until there was evidence of disease progression, intolerable toxicity, or other withdrawal criteria were met. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number | participants |
| |||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| |||||||||||||||||||||||
| Race/Ethnicity, Customized | Number | participants |
| |||||||||||||||||||||||
| Region of Enrollment | Number | participants |
| |||||||||||||||||||||||
| Child-Pugh Score | The Child-Pugh classification was used to assess the prognosis of chronic liver disease. The score employed 5 clinical measures of liver disease: encephalopathy, ascites, albumin, prothrombin time, and bilirubin. Each measure was scored from 1 (normal) and 3 (most severe derangement). The total score for the Child-Pugh assessment was calculated as the sum of the 5 contributing scores with a total possible score of 15. Chronic liver disease was classified into Child-Pugh classes A to C, employing the total score from above: 5-6=Class A; 7-9=Class B; 10-15=Class C. | Number | participants |
| ||||||||||||||||||||||
| Barcelona Stage | Barcelona Clinic Liver Cancer stage A, B, C [Franca AV et al., Braz J Med Biol Res. 2004;37(11):1689-1705]. Based on tumor burden (TB, amount of cancer in body), Child-Pugh (CP) class, Eastern Cooperative Oncology Group performance status test (PST) functional impairment [0 (Fully Active) to 5 (Death)]. Stage A [TB=single nodule or 3 nodules <3 cm, CP=A or B, PST=0 (fully active)]. Stage B (TB=single nodule >5 cm or multinodular, CP=A or B, PST=0). Stage C [TB=vascular invasion and/or metastasis, CP=A or B, PST=1 or 2 (ambulatory, restricted work activity or ambulatory, no work activity)]. | Number | participants |
| ||||||||||||||||||||||
| Macrovascular Invasion | The number of participants with macrovascular invasion (gross vascular invasion of major portal or hepatic veins) present, absent, not available, or missing. | Number | participants |
| ||||||||||||||||||||||
| Extrahepatic Metastasis Status | The number of participants with extrahepatic metastasis (metastases originating or occurring outside the liver) present or absent. | Number | participants |
| ||||||||||||||||||||||
| Hepatitis B and C Status | Number of participants with hepatitis status data (N=39). Participants whose hepatitis status is hepatitis B and C positive are not counted in the hepatitis B positive or hepatitis C positive category. | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Progression Free Survival (PFS) in Participants With Unresectable Hepatocellular Cancer Treated With the Monoclonal Antibody Ramucirumab | PFS was defined as the time from the first day of therapy to the first evidence of disease progression or death from any cause. As classified according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Participants who were alive and without disease progression and participants who did not progress and were subsequently lost to follow-up were censored at the last objective tumor assessment. | Intent-to-treat population: Participants who received at least 1 dose of ramucirumab. The number of participants censored was 13. | Median | 95% Confidence Interval | months | First dose to date of progressive disease or death due to any cause [every 3 cycles up to 18 months (1 cycle=2 weeks)] |
|
|
| ||||||||||||||||||||||||||
| Secondary | Time to Progression | The time from first day of therapy to the first date of objective evidence of progressive disease (PD) by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. PD was defined as having at least a 20% increase in sum of longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of new lesion. Time to PD was censored at the date of death or study discontinuation. | Intent-to-treat population: Participants who received at least 1 dose of ramucirumab. The number of participants censored was 20. | Median | 95% Confidence Interval | months | First dose to date of PD [every 3 cycles up to 18 months (1 cycle=2 weeks)] |
|
| |||||||||||||||||||||||||||
| Secondary | Overall Survival | Overall survival (OS) was the duration from first dose to death due to any cause. OS was censored at last contact date for participants who were alive at the end of follow-up period or lost to follow-up. | Intent-to-treat population: Participants who received at least 1 dose of ramucirumab. The number of participants censored was 10. | Median | 95% Confidence Interval | months | First dose to death due to any cause up to 37.5 months |
|
| |||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Complete Response or Partial Response (Objective Response Rate) | Objective response rate (ORR) was defined as the percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR). As classified according to Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria, CR was the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 millimeters (mm) and normalization of tumor marker level of non-target lesions. PR was having at least a 30% decrease in sum of longest diameter of target lesions. | Intent-to-treat population: Participants who received at least 1 dose of ramucirumab. | Number | 95% Confidence Interval | percentage of participants | First dose to date of objective progressive disease (PD) or death up to 18 months |
|
| |||||||||||||||||||||||||||
| Secondary | Duration of Response | Duration of response was the interval from the date of initial documented response [complete response (CR) or partial response (PR)] to the first documented date of disease progression, initiation of other (or additional) antitumor therapy was first reported, or death due to any cause. As classified according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria, CR was the disappearance of all target lesions, PR was having at least a 30% decrease in the sum of the longest diameter of target lesions, and disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Data were censored for participants who did not progress or die. | Participants who received at least 1 dose of ramucirumab and had a CR or PR. The number of participants censored 2. | Median | 95% Confidence Interval | months | Time of first response (CR or PR) to disease progression, or death due to any cause [every 3 cycles up to 18 months (1 cycle=2 weeks)] |
|
| |||||||||||||||||||||||||||
| Secondary | Number of Participants With Serum Anti-Ramucirumab Antibodies | Intent-to-treat population: Participants who received at least 1 dose of ramucirumab. | Number | participants | Prior to dosing at baseline, Cycles 4 and 7, and 30 days after end of therapy (1 cycle=2 weeks) |
|
| |||||||||||||||||||||||||||||
| Secondary | Number of Participants With Drug-Related Treatment-Emergent Adverse Events | Data presented are the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3 or higher TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered by the investigator to be related to ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section. | Intent-to-treat population: Participants who received at least 1 dose of ramucirumab. | Number | participants | First dose to 37.5 months |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Ramucirumab (IMC-1121B) | Ramucirumab (IMC-1121B): 8 milligrams per kilogram (mg/kg) administered intravenously over 1 hour, every 2 weeks. Treatment continued until there was evidence of disease progression, intolerable toxicity, or other withdrawal criteria were met. | 24 | 42 | 41 | 42 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ADRENAL INSUFFICIENCY | Endocrine disorders | MedDRA 11.0 | Systematic Assessment |
| |
| ABDOMINAL PAIN | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| ASCITES | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| CONSTIPATION | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| GASTROINTESTINAL HAEMORRHAGE | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment | Event resulted in 1 death |
|
| INTESTINAL OBSTRUCTION | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| CHILLS | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| DISEASE PROGRESSION | General disorders | MedDRA 11.0 | Systematic Assessment | Event resulted in death |
|
| FATIGUE | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| INFUSION RELATED REACTION | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| PYREXIA | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HEPATIC FAILURE | Hepatobiliary disorders | MedDRA 11.0 | Systematic Assessment | Event resulted in death |
|
| HEPATORENAL SYNDROME | Hepatobiliary disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HYPERSENSITIVITY | Immune system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| BRONCHITIS | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| CELLULITIS | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| ESCHERICHIA BACTERAEMIA | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| PNEUMONIA | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| STAPHYLOCOCCAL INFECTION | Infections and infestations | MedDRA 11.0 | Systematic Assessment |
| |
| ANOREXIA | Metabolism and nutrition disorders | MedDRA 11.0 | Systematic Assessment |
| |
| FAILURE TO THRIVE | Metabolism and nutrition disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HYPONATRAEMIA | Metabolism and nutrition disorders | MedDRA 11.0 | Systematic Assessment |
| |
| ARTHRALGIA | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| MUSCULOSKELETAL PAIN | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| PAIN IN EXTREMITY | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HEPATIC NEOPLASM MALIGNANT | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 11.0 | Systematic Assessment | Event resulted in death |
|
| ENCEPHALOPATHY | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HEPATIC ENCEPHALOPATHY | Nervous system disorders | MedDRA 11.0 | Systematic Assessment | Event resulted in death |
|
| SYNCOPE | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| CONFUSIONAL STATE | Psychiatric disorders | MedDRA 11.0 | Systematic Assessment |
| |
| MENTAL STATUS CHANGES | Psychiatric disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HYPOXIA | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| PNEUMONIA ASPIRATION | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HOSPITALISATION | Surgical and medical procedures | MedDRA 11.0 | Systematic Assessment |
| |
| LIVER TRANSPLANT | Surgical and medical procedures | MedDRA 11.0 | Systematic Assessment |
| |
| ARTERIOSCLEROSIS | Vascular disorders | MedDRA 11.0 | Systematic Assessment | Event resulted in death |
|
| FEMORAL ARTERY OCCLUSION | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HYPERTENSION | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HYPOTENSION | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ABDOMINAL DISCOMFORT | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| ABDOMINAL DISTENSION | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| ABDOMINAL PAIN | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| ABDOMINAL PAIN UPPER | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| ASCITES | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| CONSTIPATION | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| DIARRHOEA | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| DYSPEPSIA | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| GINGIVAL BLEEDING | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| NAUSEA | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| VOMITING | Gastrointestinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| ASTHENIA | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| CHILLS | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| FATIGUE | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| INFUSION RELATED REACTION | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| OEDEMA PERIPHERAL | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| PYREXIA | General disorders | MedDRA 11.0 | Systematic Assessment |
| |
| WEIGHT DECREASED | Investigations | MedDRA 11.0 | Systematic Assessment |
| |
| ANOREXIA | Metabolism and nutrition disorders | MedDRA 11.0 | Systematic Assessment |
| |
| DEHYDRATION | Metabolism and nutrition disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HYPOMAGNESAEMIA | Metabolism and nutrition disorders | MedDRA 11.0 | Systematic Assessment |
| |
| ARTHRALGIA | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| BACK PAIN | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| MYALGIA | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| PAIN IN EXTREMITY | Musculoskeletal and connective tissue disorders | MedDRA 11.0 | Systematic Assessment |
| |
| DIZZINESS | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HEADACHE | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HYPOAESTHESIA | Nervous system disorders | MedDRA 11.0 | Systematic Assessment |
| |
| ANXIETY | Psychiatric disorders | MedDRA 11.0 | Systematic Assessment |
| |
| INSOMNIA | Psychiatric disorders | MedDRA 11.0 | Systematic Assessment |
| |
| RENAL FAILURE | Renal and urinary disorders | MedDRA 11.0 | Systematic Assessment |
| |
| COUGH | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| DYSPNOEA | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| EPISTAXIS | Respiratory, thoracic and mediastinal disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HYPERTENSION | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
| |
| HYPOTENSION | Vascular disorders | MedDRA 11.0 | Systematic Assessment |
|
The duration of response results should be interpreted with caution since the sample size for this analysis was very small (2 participants).
Investigators agreed to delay independently publishing or disclosing data, findings or conclusions from the study except as part of a multi-center publication. Upon study publication or if the draft publication is not produced within approximately 6 months of the final report of the study results, investigators may independently publish, subject to confidential information review/redaction by sponsor. The sponsor may request publication delay up to 90 days to seek patent protection.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Chief Medical Officer | Eli Lilly and Company | 800-545-5979 |
| ID | Term |
|---|---|
| D006528 | Carcinoma, Hepatocellular |
| D008107 | Liver Diseases |
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000096662 | Ramucirumab |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided
| Unknown or Not Reported |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| Race Other: Hispanic |
|
| Race Other: Black and Asian |
|
| Race Other: Greek |
|
| Title |
|---|
| Measurements |
|---|
|
| Title | Measurements |
|---|
|
| C |
|
| Not Available |
|
| Missing |
|
| Hepatitis B and C Positive |
|
| Hepatitis B and C Negative |
|
|
|
|
| Participants |
|
|
| Title | Denominators | Categories | ||||
|---|---|---|---|---|---|---|
|
|